Doug Levinson

Chasing a needle-free version of a billion-dollar molecule

Doug Levinson runs Fount Bio, a small Somerville, Massachusetts company with an outsized ambition: to put hyaluronic acid where it works best, deep in the skin, without an injection.

Hyaluronic acid is everywhere in modern skin care and aesthetics. It shows up in serums, in fillers, in the roughly six-billion-dollar market for injectable products that plump and hydrate. The catch has always been physics. The molecules that do the most good are large, and large molecules do not cross the skin easily. The ones small enough to get through tend not to stay. So the industry has leaned on needles.

Fount Bio, which Levinson co-founded in 2018 with the bioengineer Samir Mitragotri, is built around a platform the company calls Flī-HA, short for functional ligand hyaluronic acid. The idea is to solve both problems at once: get hyaluronic acid across the skin surface through a topical application, and keep it there long enough to matter. The company describes its lead work, Fli-Derm, as an approach to aesthetic skin improvement that does not require the invasive delivery that current forms of HA depend on.

That combination of delivery plus stability is the whole bet. It is also a familiar shape for Levinson. For most of his career he has looked for good science stuck inside a laboratory and built the company that carries it into the world.

The Flī-HA idea, in three moves

A founding-team career

Levinson trained as a geneticist. He holds a Ph.D. in genetics from Harvard University and a bachelor's in molecular biology, earned cum laude, from the University of Massachusetts. But his working life has been less about the bench and more about building organizations around it.

He was a founding scientific team member at Millennium Pharmaceuticals, where over seven years he built the company's early immunology and inflammation program into its largest research effort, a staff of roughly 170. In 2000 he joined the scientific founding team at TransForm Pharmaceuticals, working alongside the MIT professors Bob Langer and Michael Cima. TransForm was acquired by Johnson & Johnson for $230 million in 2005.

In 2006 he moved to the investor side as a partner at Flagship Ventures. He did not stay there. Instead he went back to founding companies, one after another, each drawn from early-stage science: Cytrellis Biosystems, which developed an FDA-cleared system for aesthetic dermatology; T2 Biosystems, a nanotechnology diagnostics company that went public on the Nasdaq; and YourBio Health, which makes simple devices for blood collection and diagnostics.

Fount Bio is the latest link in that chain. The through-line is consistent: take a piece of breakthrough science, usually from an academic lab, and do the unglamorous, years-long work of turning it into a product that reaches people.

Companies he helped build

The translator's job

There is a well-known gap in science between a promising paper and a product a person can buy. Ideas die in that gap all the time, not because the science is wrong but because no one does the work of company-building around it. Levinson has spent a career in exactly that gap, pairing scientific founders like Samir Mitragotri, a widely recognized innovator in skin delivery and bioengineering, with the operating discipline to get something out the door.

Fount Bio is a test of that instinct on a market that is large, crowded, and dominated by needles. If the Flī-HA platform delivers on its promise, the pitch is simple to understand even if the chemistry is not: the benefits of hyaluronic acid, without the injection. For now, the company is doing the patient part of the work, moving its platform toward clinical proof of concept and building out its team.